Volitionrx Limited (VNRX) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
VolitionRx Announces Second Quarter 2015 Financial Results and Business Update
August 11, 2015 6:30 AM EDTNAMUR, Belgium, Aug. 11, 2015 /PRNewswire/ --Â VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the second quarter ended June 30, 2015.Â
Second Quarter 2015 and Recent Company Highlights:
Made strong progress in pursuing ongoing clinical trials in a range of cancers; in working towards regulatory approval; and in implementing large-scale laboratory automation Engaged the specialty... More